Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Arena Pharmaceuticals Inc (NASDAQ:ARNA)

1.37
Delayed Data
As of 4:00pm ET
 -0.01 / -0.72%
Today’s Change
1.32
Today|||52-Week Range
2.16
-3.52%
Year-to-Date
Why Arena Pharmaceuticals Stock Sank in 2016
Jan 13 / MotleyFool.com - Paid Partner Content
Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III
Jan 05 / Zacks.com - Paid Partner Content
VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan 11 / Zacks.com - Paid Partner Content
Alexion (ALXN) Stock Up on 10Q Filing; 2016 View Retained
Jan 05 / Zacks.com - Paid Partner Content
Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
Jan 09 / Zacks.com - Paid Partner Content
Bristol-Myers Extends Deal with Five Prime Therapeutics
Jan 05 / Zacks.com - Paid Partner Content
Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
Jan 09 / Zacks.com - Paid Partner Content
Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.
Jan 05 / Zacks.com - Paid Partner Content
Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
Jan 06 / Zacks.com - Paid Partner Content
Clovis Declares Pricing of Upsized Offering of Common Stock
Jan 04 / Zacks.com - Paid Partner Content
Genocea Stock Up on Positive Genital Herpes Infections Data
Jan 06 / Zacks.com - Paid Partner Content
Allergan Natrelle Inspira Breast Implants Approved in the U.S.
Jan 04 / Zacks.com - Paid Partner Content
Arena, Eisai Modify Marketing & Supply Agreement for Belviq
Jan 05 / Zacks.com - Paid Partner Content
Alexion (ALXN): Will the Stock Continue to Suffer in 2017?
Jan 04 / Zacks.com - Paid Partner Content